Published in BMC Med on March 14, 2011
Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One (2011) 1.88
Brain-gut-microbe communication in health and disease. Front Physiol (2011) 1.59
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
The gut microbiota: challenging immunology. Nat Rev Immunol (2011) 1.28
The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenetics (2012) 1.26
Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 1.12
Detection of dietary plant-based small RNAs in animals. Cell Res (2015) 1.05
Gut microbial communities modulating brain development and function. Gut Microbes (2012) 0.90
Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr (2014) 0.86
The influence of whole grain products and red meat on intestinal microbiota composition in normal weight adults: a randomized crossover intervention trial. PLoS One (2014) 0.82
A Basal chordate model for studies of gut microbial immune interactions. Front Immunol (2012) 0.82
Lactobacillus acidophilus CRL 1014 improved "gut health" in the SHIME reactor. BMC Gastroenterol (2013) 0.77
Eicosapentaenoic acid enhances heat stress-impaired intestinal epithelial barrier function in Caco-2 cells. PLoS One (2013) 0.77
A novel biomarker panel for irritable bowel syndrome and the application in the general population. Sci Rep (2016) 0.76
Facile, high quality sequencing of bacterial genomes from small amounts of DNA. Int J Genomics (2014) 0.75
Microbiome-Gut-Brain Axis: A Pathway for Improving Brainstem Serotonin Homeostasis and Successful Autoresuscitation in SIDS-A Novel Hypothesis. Front Pediatr (2017) 0.75
Intestinal barrier analysis by assessment of mucins, tight junctions, and α-defensins in healthy C57BL/6J and BALB/cJ mice. Tissue Barriers (2016) 0.75
Gut Health of Pigs: Challenge Models and Response Criteria with a Critical Analysis of the Effectiveness of Selected Feed Additives - A Review. Asian-Australas J Anim Sci (2015) 0.75
The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond. Visc Med (2017) 0.75
Systematic Review: The Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a Gynecological Malignancy. Int J Gynecol Cancer (2017) 0.75
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol (2008) 16.57
The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 13.87
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 10.36
Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol (1997) 8.81
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
The burden and costs of chronic diseases in low-income and middle-income countries. Lancet (2007) 8.33
Evidence-based public health: a fundamental concept for public health practice. Annu Rev Public Health (2009) 7.77
Inferences, questions and possibilities in Toll-like receptor signalling. Nature (2004) 7.57
Microbial community profiling for human microbiome projects: Tools, techniques, and challenges. Genome Res (2009) 7.12
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia (2007) 5.61
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology (2007) 5.04
Allergy, parasites, and the hygiene hypothesis. Science (2002) 5.01
GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci (1988) 4.65
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 4.58
The core gut microbiome, energy balance and obesity. J Physiol (2009) 4.45
Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature (2008) 4.42
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil (2009) 4.28
A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology (1989) 4.27
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Prevention of chronic diseases: a call to action. Lancet (2007) 3.87
Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell (2010) 3.70
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol (2004) 3.52
Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc (1990) 3.34
The biology of intestinal immunoglobulin A responses. Immunity (2008) 3.18
Fecal microbiota in early rheumatoid arthritis. J Rheumatol (2008) 2.94
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature (2010) 2.78
Diagnosing and managing common food allergies: a systematic review. JAMA (2010) 2.66
Using probiotics and prebiotics to improve gut health. Drug Discov Today (2003) 2.66
Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol (2009) 2.63
Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov (2008) 2.59
Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol (2000) 2.50
Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil (2010) 2.47
Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol (2007) 2.42
Immune responses to the microbiota at the intestinal mucosal surface. Immunity (2009) 2.41
The human intestinal microbiome: a new frontier of human biology. DNA Res (2009) 2.30
Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr (2009) 2.24
Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol (2009) 2.24
Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol (2010) 2.23
Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med (2005) 2.03
Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil (2007) 1.98
Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology (2009) 1.96
Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.96
The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology (2009) 1.94
Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol (2006) 1.89
Multiple Health Behavior Research represents the future of preventive medicine. Prev Med (2008) 1.87
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One (2007) 1.86
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut (2005) 1.84
The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol (2010) 1.77
Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis (2009) 1.77
Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology (2008) 1.77
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy (2010) 1.73
The mechanism of action of probiotics. Curr Opin Gastroenterol (2007) 1.70
Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr (2007) 1.70
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology (2008) 1.68
The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity (2009) 1.68
The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia (2010) 1.67
The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med (2007) 1.65
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol (2009) 1.65
Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther (2005) 1.63
Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy (2009) 1.61
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol (2009) 1.60
Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol (2007) 1.59
The diagnostic role of gut feelings in general practice. A focus group study of the concept and its determinants. BMC Fam Pract (2009) 1.58
Colonic bacterial flora: changing understandings in the molecular age. J Nutr (2004) 1.58
Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol (2008) 1.56
Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol (2009) 1.56
A population-based twin study of functional somatic syndromes. Psychol Med (2008) 1.53
Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res (2006) 1.52
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol Med Microbiol (2009) 1.46
Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis (2009) 1.45
Review article: bacterial translocation in the critically ill--evidence and methods of prevention. Aliment Pharmacol Ther (2007) 1.45
PASSCLAIM--gut health and immunity. Eur J Nutr (2004) 1.43
Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J Immunol (2010) 1.43
Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2010) 1.40
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci (2009) 1.39
Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl (1997) 1.37
Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol (2010) 1.37
Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol (2009) 1.36
Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci (1995) 1.35
Whole-grain consumption and transcription factor-7-like 2 ( TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr (2008) 1.35
Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis (2007) 1.34
Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil (2009) 1.34
Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut (2009) 1.31
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Molecular modulation of intestinal epithelial barrier: contribution of microbiota. J Biomed Biotechnol (2010) 1.25
Lactobacillus farciminis treatment attenuates stress-induced overexpression of Fos protein in spinal and supraspinal sites after colorectal distension in rats. Neurogastroenterol Motil (2009) 1.23
The impact of probiotic on gut health. Curr Drug Metab (2009) 1.21
Genetic approaches to functional gastrointestinal disorders. Gastroenterology (2010) 1.18
L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells. BMC Microbiol (2009) 1.17
Dietary patterns and the risk of colorectal cancer and adenomas. Nutr Rev (2010) 1.16
Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther (2009) 1.16
Nutritional management of gut health in pigs around weaning. Proc Nutr Soc (2007) 1.15
The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med (2008) 1.14